Heart Failure

Americans make many assumptions about aging, and health care providers are no exception.

Today's approval of Amgen's ivabradine makes it the first new chronic heart failure medicine that has been approved by the FDA in almost a decade.

An FDA advisory panel recommends adding a warning about the potential risk for heart failure to the labels of saxagliptin (Onglyza), saxagliptin/metformin (Kombiglyze), and alogliptin (Nesina).

Pharmacists can improve a patient's medication adherence by dispensing information beyond a drug's label.

Readmission rates among patients with heart failure, acute myocardial infarction, and pneumonia increase when psychiatric illness is also present.

Veterans with post-traumatic stress disorder face greater odds of developing heart failure.

The FDA recently granted priority review to Novarits' investigational drug LCZ696, a potential treatment for heart failure with ejection fraction.

In celebration of Heart Failure Awareness Week, the American Heart Association would like to recognize Amgen for their support of the AHA's Get With The Guidelines®-Heart Failure initiative. Amgen's support will help achieve the goal of improving care for heart failure by helping to educate physicians and patients about consistent adherence to the latest evidence-based treatment guidelines.

Digoxin is associated with a 71% increased risk of death and a 63% higher risk of hospitalization among adults diagnosed with atrial fibrillation who have no evidence of heart failure.

When association is association and causation is causation.

Approximately 6.5 million Americans are prescribed digoxin, a cardiac glycoside with a long, fascinating history.

New late-stage trial data show ivabradine reduces cardiovascular death or hospitalization for worsening chronic heart failure in patients with low systolic blood pressure.

Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.

PARADIGM-HF study results offer insight into a new heart failure treatment mechanism, neprilysin inhibition.

Hospitalization rates for heart disease and stroke have dropped significantly over the past decade.

Just 20 or 30 years ago, mention of vitamin supplementation caused many health care professionals to talk about creating "expensive urine." Today, however, vitamin and nutrient supplementation has become an important health care intervention.

Trial finds that spironolactone significantly reduced hospitalization for heart failure in heart failure patients with a preserved ejection fraction but failed to decrease the incidence of the trial's primary composite outcome.

A new review summarizes the natural history of cardiomyopathies presenting with atrial fibrillation and the importance of managing underlying pathologies.

A recent article summarizes current knowledge and discusses challenges related to atrial fibrillation and heart failure.

Heart failure patients who had hyponatremia when hospitalized were more likely to experience complications, but did not have elevated levels of short-term mortality or readmission.

Our round-up of the latest generic products.

A new analysis explores the characteristics of patients with permanent versus non-permanent atrial fibrillation, as well as those whose condition is controlled versus uncontrolled.

A new study estimates the costs of treating atrial fibrillation as well as the comparative costs of treating it with warfarin and newer oral anticoagulants.